MedwireNews: Direct ‘decongestion’ effect shown for empagliflozin in HF

Empagliflozin treatment significantly reduces pulmonary artery (PA) blood pressure in patients with heart failure (HF), show findings from the randomized EMBRACE-HF trial.

Dr. Mikhail Kosiborod, with Saint Luke’s Mid America Heart Institute, and study co-authors say theirs is the first trial to demonstrate a “decongestion effect” of sodium-glucose cotransporter (SGLT)2 inhibition in people with HF via the direct measurement of PA hemodynamics.

Read the full MedwireNews article: Direct ‘decongestion’ effect shown for empagliflozin in HF

Related Content

Feb. 10, 2021

BioNexus KC: Saint Luke’s Cardiologist Determined to Improve Diabetes Care, Outcomes
Sometimes the most dangerous element of disease is not its immediate manifestations, but secondary dangers that follow.
Feb. 1, 2021

Medscape: Cardiometabolic Subspecialty Is 'One-Stop Shop' Approach to Diabetes
A one-stop shop approach to managing the spectrum of complications in patients with type 2 diabetes with a coordinated, multidisciplinary team of clinicians has taken root in at least two U.S. medical centers, and their efforts have now joined to take this concept national through the Cardiometabolic Center Alliance.
Oct. 10, 2020

TCTMD: EMBRACE HF: Empagliflozin Cuts PA Pressure in HF With or Without Diabetes
In patients remotely monitored with an implanted device, the differences appeared to emerge early and widen with time.